Neisseria gonorrhoeae Infections - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 106 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Neisseria gonorrhoeae Infections - Pipeline Review, H1 2016

Summary


Global Markets Direct's, 'Neisseria gonorrhoeae Infections - Pipeline Review, H1 2016', provides an overview of the Neisseria gonorrhoeae Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Neisseria gonorrhoeae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neisseria gonorrhoeae Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Neisseria gonorrhoeae Infections
- The report reviews pipeline therapeutics for Neisseria gonorrhoeae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Neisseria gonorrhoeae Infections therapeutics and enlists all their major and minor projects
- The report assesses Neisseria gonorrhoeae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Neisseria gonorrhoeae Infections

Reasons to buy


- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Neisseria gonorrhoeae Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neisseria gonorrhoeae Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Neisseria gonorrhoeae Infections Overview 9
Therapeutics Development 10
Pipeline Products for Neisseria gonorrhoeae Infections - Overview 10
Pipeline Products for Neisseria gonorrhoeae Infections - Comparative Analysis 11
Neisseria gonorrhoeae Infections - Therapeutics under Development by Companies 12
Neisseria gonorrhoeae Infections - Therapeutics under Investigation by Universities/Institutes 13
Neisseria gonorrhoeae Infections - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Neisseria gonorrhoeae Infections - Products under Development by Companies 17
Neisseria gonorrhoeae Infections - Products under Investigation by Universities/Institutes 18
Neisseria gonorrhoeae Infections - Companies Involved in Therapeutics Development 19
Allergan Plc 19
BioDiem Ltd 20
Biolytics Pharma 21
Debiopharm International S.A. 22
F. Hoffmann-La Roche Ltd. 23
GlaxoSmithKline Plc 24
Melinta Therapeutics, Inc 25
Merck & Co., Inc. 26
PTC Therapeutics, Inc. 27
Recce Limited 28
Sarepta Therapeutics, Inc. 29
Sumitomo Dainippon Pharma Co., Ltd. 30
Vertex Pharmaceuticals Incorporated 31
Neisseria gonorrhoeae Infections - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BDM-I - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Biologic for Neisseria Gonorrhoeae Infection - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
dalbavancin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Debio-1453 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
delafloxacin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
edodekin alfa SR - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
gepotidacin mesylate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Neisseria gonorrhoeae (virus like particle) vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Neisseria gonorrhoeae vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Neisseria gonorrhoeae vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
PTC-672 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Recombinant Protein for Neisseria gonorrhoeae Infections - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
SM-295291 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
SM-369926 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecule to Target Bacterial Cell Wall for Tuberculosis and Gonorrhoea - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecules to Inhibit Tubulin for Oncology and Neisseria Gonorrhoeae Infections - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
solithromycin - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
VT-12008911 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Neisseria gonorrhoeae Infections - Recent Pipeline Updates 71
Neisseria gonorrhoeae Infections - Dormant Projects 96
Neisseria gonorrhoeae Infections - Product Development Milestones 97
Featured News & Press Releases 97
Dec 22, 2015: Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents 97
Sep 10, 2015: Cempra to Present Data From Antibiotic Drug Solithromycin at ICAAC/ICC 2015 Meeting 97
Nov 19, 2014: Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies 99
Sep 09, 2014: Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 99
Sep 08, 2014: Melinta Therapeutics Demonstrate Delafloxacin's Potent and Rapid Antimicrobial Activity against Neisseria Gonorrhoeae 101
Sep 06, 2014: Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin's Potent In-Vitro Activity against Complicated Urinary Tract Infection Pathogens 102
Sep 06, 2014: Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin`s Potent In-Vitro Activity against Complicated Urinary Tract Infection Pathogens 102
Sep 06, 2014: Melinta Therapeutics Reports on PK Profile of a Single Oral Dose of Delafloxacin in Support of U.S. Phase 3 Gonorrhea Program 103
Sep 04, 2014: Melinta Therapeutics Highlighting Delafloxacin and ESKAPE Candidates in Twelve Presentations at 2014 ICAAC Meeting 103
Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection 104
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 105
Disclaimer 106

List of Tables

Number of Products under Development for Neisseria gonorrhoeae Infections, H1 2016 10
Number of Products under Development for Neisseria gonorrhoeae Infections - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Neisseria gonorrhoeae Infections - Pipeline by Allergan Plc, H1 2016 19
Neisseria gonorrhoeae Infections - Pipeline by BioDiem Ltd, H1 2016 20
Neisseria gonorrhoeae Infections - Pipeline by Biolytics Pharma, H1 2016 21
Neisseria gonorrhoeae Infections - Pipeline by Debiopharm International S.A., H1 2016 22
Neisseria gonorrhoeae Infections - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 23
Neisseria gonorrhoeae Infections - Pipeline by GlaxoSmithKline Plc, H1 2016 24
Neisseria gonorrhoeae Infections - Pipeline by Melinta Therapeutics, Inc, H1 2016 25
Neisseria gonorrhoeae Infections - Pipeline by Merck & Co., Inc., H1 2016 26
Neisseria gonorrhoeae Infections - Pipeline by PTC Therapeutics, Inc., H1 2016 27
Neisseria gonorrhoeae Infections - Pipeline by Recce Limited, H1 2016 28
Neisseria gonorrhoeae Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2016 29
Neisseria gonorrhoeae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 30
Neisseria gonorrhoeae Infections - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 31
Assessment by Monotherapy Products, H1 2016 32
Number of Products by Stage and Target, H1 2016 34
Number of Products by Stage and Mechanism of Action, H1 2016 36
Number of Products by Stage and Route of Administration, H1 2016 38
Number of Products by Stage and Molecule Type, H1 2016 40
Neisseria gonorrhoeae Infections Therapeutics - Recent Pipeline Updates, H1 2016 71
Neisseria gonorrhoeae Infections - Dormant Projects, H1 2016 96